Immix Biopharma Investor Presentation Deck

Only CAR-T in BCMA-exposed multiple myeloma, a rapidly growing patient segment (1/2) Representative Treatment Results Representative patient number growth Newly diagnosed Bortezomib, lenalidomide, and (VRD) is stand dex therapy for newly diagnosed multiple myeloma -50% relapse at month 30 Standard-of-care refractory BCMA-targeted antibodies (Tecvayli-J&J; Elrexfio-Pfizer) bispecifics -50% relapse at month 11-15 ●●● IMMIX S BIOPHARMA BCMA-exposed, a rapidly growing patient segment Limited treatment options (no approved treatments) NXC-201: 75% overall response rate; 50% complete response rate "Recent studies of anti-BCMA BsAbs, ... demonstrate that patients may experience disease progression after treatment, leaving them with few other treatment options." Cohen et al, Blood, 2023 Source: https://doi.org/10.1038/s41591-023-02528-9 Nature Medicine, Lancet Oncol. 2020 October; 21(10): 1317-1330. doi:10.1016/S1470-2045(20)30452-6, ; Teclistamab in Relapsed or Refractory Multiple Myeloma New England Journal of Medicine Aug 11 2022. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Cohen et al 2023 https://doi.org/10.1182/blood.2022015526 14

View entire presentation